Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ICP-192 in previously treated FGFR2 fusion/rearranged unresectable or metastatic intrahepatic cholangiocarcinoma
CTR20222103Phase 2Active
- Sponsor
- Beijing Tiancheng Pharmaceutical Technology
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gunagratinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Beijing Tiancheng Pharmaceutical Technology. Primary endpoint: Objective response rate. Started Feb 2023; status: active.
02
Drugs
gunagratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20222103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222103.